Form 4: Clearside Biomedical Director Acquires Stock Options
SEC Form 4 Filing
Director Benjamin R. Yerxa acquired stock options in Clearside Biomedical, Inc. on June 20, 2024.
Summary
- On June 20, 2024, Benjamin R. Yerxa, a director of Clearside Biomedical, Inc., acquired stock options to purchase 45,000 shares of common stock at an exercise price of $1.15 per share.
- The options vest fully on the earlier of the company's next annual meeting or June 20, 2025, contingent upon continuous service.
- Following the transaction, Yerxa directly owns 45,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of transaction: Director acquired stock options. |
| 06/20/2025 | Vesting date: Options vest fully on the earlier of the company's next annual meeting or this date, contingent upon continuous service. |
| 06/19/2034 | Expiration date: Stock options expire. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.